Lisa Demuth Voting Record on Insulin Caps Questioned
Minnesota voters are reviewing conflicting claims regarding the Speaker's past votes on prescription drug cost caps.
Updated on Oct. 16, 2026 in Diabetes
Live Poll
Should the government mandate monthly caps on the cost of insulin for patients?
Minnesota House Speaker Lisa Demuth recently claimed on election questionnaires that she voted to cap insulin prices. Legislative records show she voted against prescription drug co-pay caps in 2023 and cost-sharing limits in 2019, though she did support the 2020 Alec Smith Insulin Affordability Act.
Why it matters
Understanding the legislative history of insulin affordability in Minnesota is essential for patients navigating current cost-sharing protections. The distinction between emergency insulin access and ongoing monthly co-pay caps remains a central point of debate for state residents.
Legislative voting records confirm Demuth supported the 2020 Alec Smith Insulin Affordability Act but opposed broader co-pay cap measures in 2019 and 2023. The 2020 law established emergency access pathways, though it lacked the comprehensive monthly co-pay limits eventually enacted later.
The players
Lisa Demuth
Minnesota House Speaker who voted for the 2020 insulin law but against later cost-sharing measures.
Alec Smith
A 26-year-old whose 2017 death while rationing insulin prompted the state's 2020 affordability legislation.
Novo Nordisk
A pharmaceutical company that manufactures insulin and employs lobbyists who advise the campaign of Lisa Demuth.
Eli Lilly
A pharmaceutical company involved in negotiations with state legislators during the 2020 insulin bill process.
Sanofi
A global healthcare company that participated in negotiations regarding Minnesota's insulin affordability legislation.
The details
The 2020 Alec Smith Insulin Affordability Act allows residents to obtain a one-time 30-day supply of insulin for $35 in emergency situations, an outcome of negotiations between state legislators and pharmaceutical companies including Eli Lilly, Sanofi, and Novo Nordisk. Broader monthly co-pay caps were only passed after subsequent shifts in state government control. These policies differ from the 2022 federal Inflation Reduction Act, which established a $35 monthly insulin co-pay cap for Medicare beneficiaries.
Timeline
2017: Alec Smith, a 26-year-old, died after rationing insulin costing $1,300 per month.
2019: Lisa Demuth voted against state insulin cost-sharing limits.
2020: The Alec Smith Insulin Affordability Act was signed into law.
2023: Lisa Demuth voted against broader prescription drug co-pay caps.
October 2026: Demuth claimed on election questionnaires she voted to cap insulin prices.
Health Landscape
The Alec Smith Insulin Affordability Act marked a critical moment in state-level efforts to address the high costs of life-saving medications. This development reflects the ongoing evolution of insulin policy as states navigate the gaps between federal protections and local cost-sharing mandates.
Minnesota patients should understand that state emergency insulin programs provide a specific 30-day safety net rather than universal monthly price caps. Patients struggling with insulin costs should consult their physician or pharmacist to verify their eligibility for current state or federal programs.
The takeaway
Legislative records provide essential clarity on the specific protections currently available to Minnesota residents. Residents should track official state health resources to confirm which cost-sharing caps apply to their specific prescription coverage.
Further reading
For more on local policy and patient resources, visit the Diabetes section.
Source note: This article includes information reported by Minnesota Reformer.
Live Poll
Should the government mandate monthly caps on the cost of insulin for patients?
